News On Japan

First Parkinson's Patient Receives iPS Cell Treatment at Kyoto University Hospital

KYOTO - Japanese pharmaceutical company Sumitomo Pharma announced on October 30 that the first patient to receive its newly approved regenerative medicine treatment for Parkinson's disease underwent a successful brain cell transplant at Kyoto University Hospital in early October, with the woman in her 50s already returning to work and recovering well.

Parkinson's disease is an intractable neurological disorder caused by the progressive loss of nerve cells in the brain, leading to symptoms such as trembling of the hands and feet. An estimated 250,000 people in Japan are affected by the disease.

Osaka-based Sumitomo Pharma has been developing a regenerative medicine product called Amchepry, which involves transplanting nerve cells derived from induced pluripotent stem (iPS) cells into the brain to improve symptoms.

The treatment received conditional approval for manufacturing and marketing from Japan's Ministry of Health, Labor and Welfare in March 2026, marking a significant step toward making regenerative medicine available to patients with Parkinson's disease.

At a press conference on October 30, Sumitomo Pharma revealed that the first transplant using Amchepry had been performed at Kyoto University Hospital in early October. The patient, a woman in her 50s, has already resumed working, and her postoperative recovery is progressing smoothly, according to the company.

Sumitomo Pharma President Toru Kimura said the company was committed to completing the necessary clinical evaluation and securing full regulatory approval as quickly as possible. "We will make a company-wide effort to complete the Phase 4 trial as soon as possible and obtain full approval," Kimura said.

The company plans to administer Amchepry to 35 patients by around 2029 as part of its efforts to confirm the treatment's safety and effectiveness.

The program represents an important step toward establishing iPS cell-based regenerative medicine as a treatment option for Parkinson's disease, although the therapy's long-term safety and effectiveness will need to be confirmed through further clinical evaluation.

Source: YOMIURI

News On Japan
POPULAR NEWS

Toyota Motor will begin operating fully autonomous taxis in 2027 through a partnership with U.S. self-driving technology company Waymo, marking a major step in the Japanese automaker's efforts to expand driverless transportation services.

Mount Fuji has received its first snowcap of the season, the Japan Meteorological Agency announced on October 30, after temperatures at the summit plunged to minus 9.4 degrees Celsius, marking the arrival of winter conditions on Japan's highest mountain.

U.S. intelligence agencies suspect that a Chinese female intelligence operative developed a close relationship with Nvidia CEO Jensen Huang in an attempt to obtain confidential corporate and U.S. government information, according to a report published by The New York Times on October 29th.

The Japanese government has asked major telecommunications operators to forcibly block access to websites believed to contain personal information stolen in a cyberattack on GMO, it emerged on October 29th, as authorities moved to prevent further exposure of sensitive data online.

Typhoon No. 31 was located near Minamitorishima Island in the Pacific Ocean, as of 3 a.m. on October 30, and was expected to approach the Ogasawara Islands south of Tokyo over the October 31-November 1 weekend while maintaining very strong intensity, bringing a growing risk of dangerously high waves, powerful swells and extremely rough seas.

MEDIA CHANNELS
         

MORE Sci-Tech NEWS

Japanese pharmaceutical company Sumitomo Pharma announced on October 30 that the first patient to receive its newly approved regenerative medicine treatment for Parkinson's disease underwent a successful brain cell transplant at Kyoto University Hospital in early October, with the woman in her 50s already returning to work and recovering well.

Japan's ports have long been the backbone of one of the world's most export-driven economies.

A company in Kagoshima has developed a new garbage collection station that uses specially shaped wires and rollers instead of conventional nets to prevent crows from scattering household waste, offering a cleaner and more convenient solution to a persistent problem in Japan's urban neighborhoods.

Japan has chosen a small, irregularly shaped moon orbiting Mars rather than the planet itself for its latest space exploration mission, taking advantage of Phobos' extremely weak gravity and lack of atmosphere to make collecting extraterrestrial samples and returning them to Earth far easier and less expensive, while potentially unlocking secrets about the history of Mars and the origins of water and organic materials in the solar system.

Japan's H3 rocket successfully launched the Martian Moons eXploration (MMX) spacecraft from the Tanegashima Space Center in Kagoshima Prefecture on the morning of October 20th, placing the probe into its planned orbit in the first stage of a mission to collect samples from one of Mars' moons and return them to Earth.

JR West has unveiled multifunctional railway maintenance machinery, including a heavy-duty single-arm robot and a mass-produced humanoid robot, as part of efforts to address labor shortages and reduce workplace accidents in railway maintenance operations.

Subaru unveiled experimental vehicles equipped with a new driver assistance system on October 18, introducing technology that can automatically guide a vehicle to a safe roadside location when the driver becomes incapacitated, with plans to introduce the system in production models by the late 2020s.

Japan will launch its H3 rocket No. 10 from the Tanegashima Space Center in Kagoshima Prefecture at 4:41 a.m. on October 20, carrying a spacecraft designed to collect rocks and sand from Phobos, one of Mars' two moons, and return them to Earth in what would be the world's first successful mission of its kind.